第五代超灵敏前列腺特异性抗原检测用于根治性前列腺切除术后监测:3年随访
该研究评估第五代超灵敏PSA免疫分析(MesoScale,检测下限0.0035 pg/mL)在20例根治性前列腺切除术后患者系列血清样本(N=100)中监测生化复发(BCR)的价值,并与第三代ELISA(检测下限1 pg/mL)比较。MesoScale可定量全部样本并检出8/20例BCR,ELISA仅能定量38%样本并检出7/20例BCR,但两种方法检出BCR的中位时间无显著差异。结论认为超灵敏PSA技术可追踪0.003-1 pg/mL的微小变化,但该浓度范围内的PSA动力学和最低值波动,低于2 pg/mL的升高不能可靠提示BCR。
要点
- 第五代超灵敏PSA分析可定量全部术后血清样本,检测下限0.0035 pg/mL。
- 超灵敏PSA在低于2 pg/mL范围的动力学波动,升高不能可靠提示生化复发。
- 生化复发组Gleason评分高于非复发组,其他临床病理参数无显著差异。
核心结论
- 超灵敏PSA技术可追踪0.003-1 pg/mL范围的微小变化,但低于2 pg/mL的PSA动力学和最低值波动,升高不能可靠提示生化复发。
研究设计与样本
- 研究纳入20例根治性前列腺切除术后患者,连续采集100份系列血清样本,同时用第三代ELISA(检测下限1 pg/mL)和第五代MesoScale超灵敏PSA免疫分析(检测下限0.0035 pg/mL)测定PSA。
主要发现
- ELISA仅能定量38%的术后样本,检出7/20例生化复发;MesoScale可定量全部样本,检出8/20例生化复发。
- 基于ELISA和MesoScale检出BCR的中位时间分别为1016天和949天,两者无显著差异。
- 生化复发组Gleason评分高于非复发组,其他临床病理参数无显著差异。
临床怎么用
- 第五代超灵敏PSA分析可用于术后极低浓度PSA的追踪,但低于2 pg/mL的PSA升高需谨慎解读,不宜单独作为生化复发的可靠指标。
局限性
- 样本量较小(20例患者、100份样本),随访3年,结论需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We investigated an ultrasensitive prostate-specific antigen (uPSA) immunoassay (MesoScale; lower limit of detection (LLD) of 0.0035 pg/mL) to monitor patients with prostate cancer (PCa) following radical prostatectomy (RP) and to examine whether changes in PSA in the conventionally undetectable range (<1 pg/mL) can predict biochemical relapse (BCR). METHODS: We measured uPSA in serial serum samples (N = 100) collected from 20 RP cases with a third-generation ELISA (LLD of 1 pg/mL) and the fifth-generation MesoScale assay. We analyzed the PSA nadir changes to classify patients into BCR or non-BCR groups, observed the trends in PSA kinetics, and associated BCR status with clinicohistopathological features. RESULTS: The ELISA could quantify PSA in only 38% of the RP samples, detecting BCR in 7 of 20 patients with PCa. The MesoScale assay quantified PSA in all samples, showing 8 of 20 patients with BCR. However, there was no significant difference between the median time to BCR detection based on ELISA (1016 days) compared with MesoScale data (949 days). Gleason scores were higher in the BCR groups compared with non-BCR. There was no significant difference for other clinicohistopathological parameters. CONCLUSIONS: The uPSA MesoScale technology could track miniscule changes in serum PSA in the range of 0.003-1 pg/mL in all RP cases. However, PSA kinetics and nadir at concentrations <2 pg/mL fluctuated, and increases below this range could not reliably suggest signs of BCR. Instead, ultrasensitive fifth-generation PSA assays may hold clinical potential for measuring the low concentrations of PSA in women for various medical contexts.
引用
- Ren AH, Soosaipillai A, Mathew A, et al. Utility of a Fifth-Generation Ultrasensitive Prostate-Specific Antigen Assay for Monitoring Prostate Cancer Patients after Radical Prostatectomy with 3 Years of Follow-Up. Clin Chem. 2020. PMID: 33001184. doi:10.1093/clinchem/hvaa176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。